This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

Browse

KLOW

KLOW is a community-developed multi-peptide blend popularized in pep-pedia and biohacker peptide forums for chronic inflammation, wound healing, and skin/hair regeneration.

Aliases (5)
KLOW Protocol · KLOW blend · K-L-O-W stack · KPV+LL-37+GHK-Cu+BPC-157+TB-500 · GHK-Cu+TB-500+BPC-157+KPV blend
TYPICAL DOSE
| 1 | 250 mcg SC daily | 100 mcg ×2
Daily SC
ROUTE
CYCLE
Typical duration
STORAGE
Refrigerated

Overview

What is KLOW?

KLOW is an injectable peptide stack combining KPV, LL-37, GHK-Cu, BPC-157, and TB-500 (or TB4-Frag). It is used as a multi-target healing and anti-inflammatory protocol in performance and longevity practice.

Key Benefits

Accelerates wound healing and tissue repair, broad anti-inflammatory and antimicrobial action, improved joint and tendon recovery, and skin/hair regeneration support from the GHK-Cu component.

Mechanism of Action

Combines complementary peptides: KPV (anti-inflammatory melanocortin fragment), LL-37 (cathelicidin antimicrobial/immunomodulator), GHK-Cu (copper-binding regenerative tripeptide), BPC-157 (cytoprotective angiogenic peptide), and TB-500 (actin-binding regenerative thymosin beta-4 fragment).

Stack Components

KPV

Anti-inflammatory tripeptide (α-MSH C-terminal fragment) — suppresses NF-κB and works through MC1R/MC5R for systemic and gut-local inflammation control.

250-500 mcg SC daily OR oral
LL-37

Cathelicidin antimicrobial peptide and immune modulator — broad-spectrum antibacterial/antiviral activity plus chemotactic recruitment of immune cells to repair sites.

100-200 mcg SC, 2-3× weekly
GHK-Cu

Copper-binding regenerative tripeptide — drives collagen synthesis, hair-follicle stimulation, and skin remodeling; key dermal/cosmetic lane in the stack.

1-3 mg SC daily OR topical 0.05-0.2%
BPC-157

Cytoprotective angiogenic peptide — VEGFR2-driven vascular repair, Schwann-cell migration for peripheral nerves, and gut mucosal protection.

250-500 mcg SC, 1-2× daily
TB-500

Actin-binding thymosin β4 fragment — drives cell migration, anti-fibrosis, and systemic regeneration that complements BPC-157's local repair signal.

2 mg SC, 2× weekly
Reconstitution Lyophilized peptide

Reconstitute lyophilized peptide with bacteriostatic water (BAC) using sterile technique. Calculator below converts vial mg + diluent mL into syringe units.

Vial size
80 mg / vial
Steps
  1. 1 Wipe BAC water vial + peptide vial stoppers with isopropyl alcohol.
  2. 2 Draw the planned diluent volume into a 1 mL syringe.
  3. 3 Inject diluent slowly down the inside wall of the peptide vial — do NOT spray onto powder.
  4. 4 Swirl gently (do not shake) until fully dissolved. Solution should be clear.
  5. 5 Label vial with date reconstituted; refrigerate 2-8 °C.
  6. 6 Use within 30 days for most peptides (BPC-157 / TB-500 ~ 60 days at 4 °C).
Open dose calculator for KLOW

Research Indications

Most Effective

Multi-Modal Healing

Addresses tissue repair through multiple complementary pathways

Most Effective

Enhanced Tolerability

KPV may reduce injection site reactions compared to GLOW

Most Effective

Convenience Factor

Single injection versus four separate peptides

Effective

Post-Surgical Recovery

User reports of enhanced healing - no clinical validation

Effective

Sports Injury Support

Athletes report benefits - banned by WADA

Effective

Skin Rejuvenation

Aesthetic applications reported but unverified

Peptide Interactions

GLOW Protocol
Caution

KLOW already contains all GLOW components plus KPV - combining would result in double dosing of base peptides

Ipamorelin
Compatible

No studies on combination - theoretical compatibility based on different mechanisms

NAD+
Compatible

No data on combining KLOW with NAD+ - both affect cellular processes through different pathways

Anticoagulants
Caution

Components may affect wound healing and clotting - medical supervision required

Growth Hormone
Avoid

Multiple components affect GH pathways - risk of excessive stimulation

Immunosuppressants
Caution

Components may interfere with immunosuppressive therapy - consult physician

What to Expect

  • Week 1
    Tolerability and dose-response.
  • Week 2-4
    Early effect window.
  • Week 4-8
    Peak benefit assessment.
  • Week 8+
    Cycle decision point.

References

Pep-Pedia KLOW Protocol page

pep-pedia.com

community-canonical 4-peptide blend definition

View Study

Vital Body Therapeutics — KLOW protocol article

vitalbodytherapeutics.com

vendor/practitioner write-up of 5-peptide variant

View Study

BPC-157 component file

bpc-157.md

full mechanism + evidence + sourcing for the angiogenesis/nerve lane

View Study

TB-500 component file

tb-500.md

actin remodeling + cell migration mechanism

View Study

GHK-Cu component file

ghk-cu.md

collagen synthesis + copper redox

View Study
Was this helpful?
Your feedback shapes what we research deeper.

How was your experience with this compound?

Anonymous · one vote per session · results below at 5+ votes.

Loading…

See something off?

Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.

Discussion — click to load
Loading…
Continue: Extended research →
Our verdict, decision matrix, deep dives, controversies, sources

Related compounds

Cross-referenced from KLOW

More in Peptide · Stack

5 compounds in bucket